Cargando…
Harnessing the immunotherapeutic potential of CDK4/6 inhibitors in melanoma: is timing everything?
CDK4/6 inhibitors (CDK4/6i) were developed as a cancer therapeutic on the basis of their tumor-intrinsic cytostatic potential, but have since demonstrated profound activity as immunomodulatory agents. While currently approved to treat hormone receptor-positive breast cancer, these inhibitors are und...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021218/ https://www.ncbi.nlm.nih.gov/pubmed/35444175 http://dx.doi.org/10.1038/s41698-022-00273-9 |